Mymetics

Successful Results for Mymetics Corporation's Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations

NYON, Switzerland, September 16 /PRNewswire-FirstCall/ -- Mymetics Corporation (OTCBB: MYMX), a vaccine development company, is pleased to announce their preliminary SHIV challenge results on non-human primates previously immunized with the Company's mucosal HIV-AIDS vaccine designed for trigg...

Mymetics' HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model

... mymetics Also Announces Deal for Vaccine Delivery System N...place as early as the third quarter of 2008." mymetics also announced that it has signed an exclusive lic...ced to enter clinical testing for HIV vaccines." mymetics Vaccine Program Background Worldwide, over 85% o...

Mymetics' HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model

...nst HIV in non-human primates. In the coming year, mymetics intends to conduct another study in non-human prim...d begin phase I testing some time in late 2008." mymetics Vaccine Program Background Worldwide, over 85 pe...infection, thus preventing HIV-1 infection. mymetics has combined three important concepts in its vacci...

Mymetics in Biological Technology

Mymetics Corporation Information to be Available Through Standard & Poor's Market Access Program

...ors. As part of the program, a full description of mymetics Corporation will also be published in the Daily Ne...e of any security or other financial instrument. mymetics have further contracted with BlueSkyMLS http://ww...ogram. Ernest Luebke, Chief Financial Officer of mymetics Corporation stated "We are very pleased with the l...

Mymetics Corporation Important Shareholders Information Conference Call

...nd other infectious diseases, including the human immunodeficiency virus, or HIV, the virus that leads to acquired immunodeficiency syndrome, or AIDS. mymetics has also recently acquired from a close scientific partner an advanced malaria vaccine project currently in phase Ib clinical trials. Additional appli...